Pharmaceutical giant Merck has officially unveiled extensive clinical data from its broad oral antiviral pipeline at the HIV Glasgow 2026 international congress. The latest medical trials highlighted highly favorable patient-reported outcomes and strong efficacy subgroups for an investigational once-weekly oral combination treatment. Additionally, the presentation detailed a groundbreaking once-monthly oral regimen for HIV pre-exposure prophylaxis (PrEP), signaling a major shift toward long-acting, highly convenient prevention methods that reduce pill burden and enhance global healthcare accessibility.
About the Author
